Conference Interview #22 of 25
Sarah Anwar, MDLinx
San Antonio Breast Cancer Symposium 2017
San Antonio, Texas, United States | December 05-09, 2017
Dr. Sparano’s research explored the association between circulating tumor cells and late recurrence in early stage breast cancer. This trial enrolled a subset of patients who were previously enrolled in the E5103 trial, “which was a high-risk population that included patients with a node-positive disease, or high-risk node-negative disease,” between 4.5 and 7.5 years after initial diagnosis of HER2- stage II-III breast cancer, with no clinical evidence of recurrence.
The research group aimed to answer 2 main questions: What is the prevalence of CTC-positivity in the patients? Is the presence of CTC in the blood associated with increased risk of recurrence?